GH SecretagogueSubcutaneous

IGF-1 DES (1,3)

Also known as: DES(1-3)-IGF-1 · Des-IGF

Truncated IGF-1 missing the first three N-terminal amino acids. The truncation prevents IGFBP binding, making it 5–10x more potent locally but with a much shorter systemic half-life than LR3.

At a glance

Half-life: 30 minutes
Common route: Subcutaneous
Typical dose range: 20–75mcg
Stability (reconstituted): 14days refrigerated

Best timing

Injected locally into the trained muscle immediately pre- or intra-workout. Short half-life means effect is concentrated near injection site.

Contraindications

Active cancer
Pregnancy
Diabetic retinopathy
Severe hypoglycemia history

Watch symptoms

Hypoglycemia — less systemic than LR3 but still significant
Localized muscle fullness or pump that persists hours after training
Injection site soreness
Hunger spike post-workout
Hand or foot numbness at higher doses

Citations

The primary literature.

01Des(1-3)IGF-I: an N-terminally truncated form of insulin-like growth factor-I with biological activityPubMed
02Comparison of the biological activities of insulin-like growth factor-1 and its truncated analog des(1-3)IGF-1PubMed

Back to library